D.C. Circuit Upholds Approval Of Drug; Not ‘Same’ Under Orphan Drug Act
WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals found that the U.S. Food and Drug Administration’s approval of a drug to treat narcolepsy during Jazz Pharmaceuticals Inc.’s...To view the full article, register now.
Already a subscriber? Click here to view full article